NICE recommends Tecfidera
In final guidance, the National Institute for Health and Care Excellence (NICE) has recommended the use of Tecfidera (dimethyl fumarate; Biogen Idec) as a treatment option for adults with relapsing–remitting multiple sclerosis only if they do not have highly active or rapidly evolving severe relapsing–remitting multiple sclerosis and the manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066295
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com